Jun Miki
Overview
Explore the profile of Jun Miki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
189
Citations
914
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayashi A, Kawabe M, Yamamoto I, Ohki Y, Kobayashi A, Urabe F, et al.
Clin Exp Nephrol
. 2025 Mar;
PMID: 40067572
Background: Solid organ transplant recipients taking immunosuppressive drugs are at greater risk of severe COVID-19 than the general population. In particular, kidney transplant recipients (KTRs) are known to have lower...
2.
Yajima S, Hata S, Masumori N, Matsuoka Y, Sawada A, Miki J, et al.
Int J Urol
. 2025 Mar;
PMID: 40062520
Objectives: This study aimed to assess the treatment preferences of Japanese patients with muscle-invasive bladder cancer (MIBC) by quantifying their trade-offs between treatment attributes using a discrete choice experiment (DCE)....
3.
Urabe F, Tashiro K, Muramoto K, Yanagisawa T, Katsumi K, Takahashi H, et al.
Urol Oncol
. 2025 Mar;
PMID: 40023743
Background: Androgen receptor-signaling inhibitors (ARSIs) have significantly changed the preferred treatments for metastatic castration-sensitive prostate cancer (mCSPC). Despite such advances, the prognostic significance of metastases at specific sites remains unclear....
4.
Shibata K, Iwatani K, Imai Y, Yoshihara K, Miyajima K, Fukuokaya W, et al.
In Vivo
. 2025 Feb;
39(2):824-833.
PMID: 40010955
Background/aim: The lung immune prognostic index (LIPI), which is determined by assessing the derived neutrophil-to-lymphocyte ratio in conjunction with the level of lactate dehydrogenase, predicts outcomes in various cancers. Its...
5.
Tsuboi I, Matsukawa A, Kardoust Parizi M, Schulz R, Mancon S, Fazekas T, et al.
Clin Genitourin Cancer
. 2025 Feb;
23(2):102306.
PMID: 39952876
Despite currently used intravesical therapies in non-muscle-invasive bladder cancer (NMIBC), the rate of intravesical recurrence remains very high. We aimed to evaluate the effectiveness of adding nonintravesical interventions to standard...
6.
Hara S, Fukuokaya W, Miki J, Taoka R, Saito R, Matsui Y, et al.
Int J Urol
. 2025 Feb;
PMID: 39907200
Objective: To examine the association between substaging and outcomes following radical cystectomy (RC) in patients with stage III bladder cancer. Methods: We conducted a retrospective observational study using nationwide data...
7.
Yanagisawa T, Mori K, Matsukawa A, Kawada T, Katayama S, Laukhtina E, et al.
Cancer Immunol Immunother
. 2025 Feb;
74(3):76.
PMID: 39891702
Recent phase 3 randomized controlled trials (RCTs) demonstrate the promising impact of immune checkpoint inhibitor (ICI)-based combination therapies on locally advanced or metastatic urothelial carcinoma (UC). However, comparative data on...
8.
Matsukawa A, Litterio G, Cormio A, Miszczyk M, Kardoust Parizi M, Fazekas T, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39857987
: The addition of androgen receptor pathway inhibitors (ARPIs) to androgen deprivation therapy (ADT), with or without docetaxel (Doc), is currently recommended for metastatic, hormone-sensitive prostate cancer (mHSPC). Recently, the...
9.
Matsukawa A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, Fazekas T, Tsuboi I, et al.
Eur Urol Focus
. 2025 Jan;
PMID: 39848859
Background And Objective: There is an established association between secondary bladder cancers (SBCs) and radiotherapy (RT) for prostate cancer (PC), which remains a significant concern. Our aim was to update...
10.
Urabe F, Kadena S, Tashiro K, Tokuoka K, Taneda Y, Fujiwara K, et al.
Jpn J Clin Oncol
. 2025 Jan;
PMID: 39820640
Background: Despite its demonstrated efficacy in prolonging overall survival (OS) and delaying skeletal-related events in the ALSYMPCA trial, the optimal timing of radium-223 initiation remains unclear. This study investigated factors...